Immunodiagnostics Market is expected to reach US$ 34,487.80 million by 2030

Enzyme-Linked Immunosorbent Assays (ELISA) Segment to Dominate Immunodiagnostics Market During 2022–2030

According to our new research study on “Immunodiagnostics Market Forecast to 2030 – COVID-19 Impact and Global Analysis – by Product, Clinical Indication, and End User,” the immunodiagnostics market size is expected to reach US$ 34,487.80 million by 2030 from US$ 19,218.89 million in 2022; it is estimated to record a CAGR of 7.6% from 2022 to 2030. The report highlights the trends prevalent in the global immunodiagnostics market, along with drivers and deterrents affecting it’s the market growth.

Based on product, the immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held the largest market share in 2022. The chemiluminescence immunoassays (CLIA) segment is anticipated to record a significant growth rate during the forecast period. Enzyme-linked immunosorbent assay (ELISA) frequently measures antibodies, proteins, antigens, and glycoproteins in biological samples. ELISA is used for HIV diagnosis, pregnancy tests, and cytokine or soluble receptor measurement (from cell supernatant or serum). It has replaced radioimmunoassay (RIA) to become one of the most common and reliable diagnostic tools. Moreover, the ELISA technique advancement led to the development of quantitative PCR, fluorogenic, and electro-chemiluminescent reporters to generate signals. Further, ELISA, along with lateral flow immunoassays, was widely used during the COVID-19 pandemic to identify individuals having antibodies developed against SARS-CoV-2, thus driving the immunodiagnostics market growth.

Global Immunodiagnostics Market, by Region, 2022 (%)

Source: The Insight Partners Analysis
 
Impact of COVID-19 Pandemic on Immunodiagnostics Market
The medical industry across the globe witnessed a chaotic situation, with increased demand for clinical diagnostics and therapeutic systems in hospitals. With the increasing infection rate and the rising demand for diagnosis caused by the COVID-19 pandemic, the market experienced a positive impact across the world. Healthcare facilities, clinical laboratories, and pharmaceutical and biotech companies preferred advanced diagnostic techniques and systems to handle the burden of COVID-19. 

The rising number of COVID-19 patients led to a positive impact on the market. In March 2021, Eurofins' Clinical Enterprise, Inc. obtained an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a direct-to-consumer (DTC) version of its EmpowerDX COVID-19 Home Collection Kit. The Eurofins at-home COVID-19 nasal PCR kit is one of the first over-the-counter SARS-CoV-2 at-home test kits. Similarly, in March 2020, the US FDA issued EUA to Abbott for its fastest available molecular point-of-care test to detect novel coronavirus (COVID-19), which delivers positive results in ~5 minutes and negative results in around 13 minutes. Thus, the rise in product launches is supporting the immunodiagnostics market growth. 

Abbott Laboratories, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Danaher Corp, Thermo Fisher Scientific Inc, PerkinElmer Inc, Shenzhen Mindray Bio-Medical Electronics Co Ltd, bioMerieux SA, Svar Life Science AB, and Siemens Healthineers AG are a few key companies operating in the immunodiagnostics market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name. 

A few of the recent developments in the global immunodiagnostics market are mentioned below:

• In May 2023, Thermo Fisher Scientific announced that the US FDA had cleared its immunoassays, B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers. These immunoassays assess risks and clinical management of preeclampsia, a severe pregnancy complication.
• In April 2023, Thermo Fisher Scientific announced a partnership with ALPCO-GeneProof, a global leader in diagnostics. The partnership has helped bring TaqPath Menu | GeneProof PCR kits into the market.
• In July 2022, Abbott Diagnostics announced its participation in American Association for Clinical Chemistry (AACC) 2022. In the exhibition, the company demonstrated its diagnostics systems and analyzers.
• In May 2022, Roche and The Global Fund to Fight AIDS, Tuberculosis and Malaria joined forces to build and strengthen diagnostic capacity and pandemic preparedness in low-and middle-income countries fighting against HIV and tuberculosis (TB). 
• In September 2022, Mindray launched the ToRCH Panel. With this panel, the company offers high-quality assays to meet different clinical needs. Mindray ToRCH kits support diverse sample types with less quality controls and sample volumes, which ensures great ease and convenience during clinical detection. 

The report segments the global immunodiagnostics market as follows:  
Based on product, the immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others.  Based on clinical indication, the market is divided into infectious diseases, Hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. By end user, the immunodiagnostics market is categorized into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. Geographically, the immunodiagnostics market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). 

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com